Literature DB >> 2626520

Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine.

S R Marder, T Van Putten, M Aravagiri, J W Hubbard, E M Hawes, G McKay, K K Midha.   

Abstract

We evaluated the metabolism of fluphenazine (FLU) in patients treated with either the oral form of FLU or with fluphenazine decanoate (FD). Samples for both patient populations were analyzed using four different radioimmunoassays developed in our laboratories for fluphenazine, fluphenazine sulfoxide (FS), 7-hydroxy fluphenazine (7OHFLU), and fluphenazine N-oxide (FLUNO). In patients receiving oral FLU the levels of FS and 7OHFLU were significantly higher than levels of FLU. In patients receiving FD, the levels of metabolites were significantly lower than FLU levels. This supports the view that drug metabolism is likely to be a more important factor for patients treated with an oral as opposed to a depot phenothiazine neuroleptic.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2626520

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  6 in total

1.  A method to estimate in vivo D2 receptor occupancy by antipsychotic drugs.

Authors:  R A Roemer; E Richelson; C Shagass; L Leventhal
Journal:  J Psychiatry Neurosci       Date:  1996-11       Impact factor: 6.186

Review 2.  Fluphenazine (oral) versus placebo for schizophrenia.

Authors:  Hosam E Matar; Muhammad Qutayba Almerie; Stephanie Sampson
Journal:  Cochrane Database Syst Rev       Date:  2013-07-17

Review 3.  Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.

Authors:  K K Midha; J W Hubbard; S R Marder; B D Marshall; T Van Putten
Journal:  J Psychiatry Neurosci       Date:  1994-07       Impact factor: 6.186

Review 4.  Pharmacokinetic optimisation of the treatment of psychosis.

Authors:  A E Balant-Gorgia; L P Balant; A Andreoli
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

5.  Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.

Authors:  Simon Zhornitsky; Emmanuel Stip
Journal:  Schizophr Res Treatment       Date:  2012-02-15

Review 6.  Fluphenazine (oral) versus placebo for schizophrenia.

Authors:  Hosam E Matar; Muhammad Qutayba Almerie; Stephanie J Sampson
Journal:  Cochrane Database Syst Rev       Date:  2018-06-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.